Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

182.31 -4.48 (-2.40%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
81 82 Next >
Large Cap Biopharma And Healthcare, A Port In A Storm
Healthcare and biopharma show nice gains in a volatile week. 
Via Talk Markets
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts. 
Via The Motley Fool
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early
The company reported $1.1 million in adjusted operating income, well ahead of expectations for a $2.6 million loss. 
Via Investor's Business Daily
A Closer Look at AbbVie's Options Market Dynamics
Via Benzinga
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
7 Stocks Set for a Major Bull Run
Explore top stocks to buy, leading in social media, semiconductors, entertainment, restaurants, payments and biotechnology. 
Via InvestorPlace
3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle
Here are three powerhouse growth stocks long-term investors may want to hone in on during this part of the market cycle. 
Via InvestorPlace
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
AbbVie had a solid quarter, accelerating growth and giving positive guidance that has analysts lifting their price targets and the stock advancing. 
Via MarketBeat
Topics Earnings Intellectual Property
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Merck stock is down more than 4% after lowering its 2024 earnings outlook, but if you look beyond the headline numbers, this could be a chance to buy the dip 
Via MarketBeat
3 High-Yield Dividend Stocks That Are Looking Super Hot
Discover high-yield dividend stocks offering solid returns. Learn about AbbVie, Target, and Abbott for reliable income and growth potential. 
Via InvestorPlace
3 Dividend-Paying ETFs to Secure Your Passive Income Stream
Passive income and ETFs represent two compelling market concepts. Why not bring the two together with dividend-paying ETFs? 
Via InvestorPlace
Topics ETFs
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
From Alector, Inc.
Via GlobeNewswire
AbbVie Wins Analyst Confidence with Q2 Beat, Diverse Portfolio Fuels Long-Term Growth Expectations
AbbVie reports Q2 earnings with adjusted EPS of $2.65, surpassing expectations. Net revenues hit $14.46 billion, reflecting a 4.3% increase. Analysts maintain a positive outlook with increased price... 
Via Benzinga
Lockheed Martin To Rally Over 14%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Why AbbVie Stock Was Cruising Higher on Thursday
The market was impressed with a notable increase in full-year guidance. 
Via The Motley Fool
AbbVie (ABBV) Q2 2024 Earnings Call Transcript
ABBV earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q2 2024
ABBV stock results show that AbbVie beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown. 
Via Benzinga
Topics Economy
AbbVie Stock News: Why ABBV Is the Top Trending Ticker Today
AbbVie stock is the top trending ticker on Yahoo Finance Thursday earnings news has ABBV investors pumped up this morning. 
Via InvestorPlace
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
AbbVie Inc. reported Q2 adjusted EPS of $2.65, beating the $2.57 consensus, with net revenues at $14.46 billion. Immunology sales rose to $6.97 billion, while Humira declined 29.8%. Oncology and... 
Via Benzinga
Topics Earnings
AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance
The company's biggest drug, Humira, is about to give way to Skyrizi when it comes to sales power. 
Via Investor's Business Daily
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Is AbbVie the Best Dividend Stock for You?
The drug company has a famously strong dividend record -- and that looks set to continue. 
Via The Motley Fool
7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio
With political rumblings poised to make things exciting, investors may turn to the stability of trustworthy dividend stocks. 
Via InvestorPlace
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
AbbVie Earnings Preview: Will Humira's Expiry, New CEO Fuel A Bullish Surge?
AbbVie will report Q2 earnings on Thursday. Investors watch for Humira impact and signs of recovery under new CEO. 
Via Benzinga
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech... 
Via Benzinga
Topics Government Stocks
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.